Topic:

Partnering

Latest Headlines

Latest Headlines

Pharmaxis sells NASH candidate to Boehringer, transforming financial outlook

Boehringer Ingelheim has exercised an option to buy PXS4728A from Australia-based Pharmaxis and develop it for the treatment of the liver-related condition NASH with the candidate also showing potential in chronic obstructive pulmonary disease.

Venter's HLI teams up with Cleveland Clinic for human genomics collaboration

J. Craig Venter's Human Longevity (HLI) is joining forces with Cleveland Clinic for a human genomics collaboration aimed at disease discovery, a little more than a year after the company kicked off operations with the promise of building the world's biggest human gene-sequencing platform.

Regenerative push grows as Green Cross, POSCO Capital buy stake in U.S.-based Juventas

South Korea's Green Cross Holdings and POSCO Capital joined to buy a $7.5 million stake in U.S.-based Juventas Therapeutics, pushing a regenerative and biologics growth strategy that has seen recent deals in China and Russia.

Eli Lilly to work with Sanford-Burnham on autoimmune diseases

Eli Lilly has signed up to collaborate with researchers at Sanford-Burnham on a new generation of immunological drugs for diseases like lupus, Sjögren's syndrome, inflammatory bowel disease and other autoimmune disorders.

Abbott and GE join forces for atrial fibrillation Dx

Abbott and GE Healthcare are teaming up for a diagnostics collaboration aimed at improving treatment for patients with atrial fibrillation, planning to combine the companies' innovative technology to speed up diagnosis for individuals with heart rhythm disorders.

Fresh off $250M investment from Roche, Foundation Medicine testing volume up 67%

Foundation Medicine provided additional detail about Roche's multimillion-dollar investment in the cancer-focused molecular diagnostic company during its Q1 2015 earnings call.

China's BeiGene completes $97M financing for targeted oncology candidates

China's BeiGene said it has completed financing of more than CNY450 million ($75 million) from initial angel and strategic investors as well as new investors Hillhouse Capital and CITIC PE, joined by an unnamed "blue chip U.S. public investment fund" specializing in life sciences.

Contrave trial tussle brews between Takeda, Orexigen with Cleveland Clinic on the scene

A tussle over the termination of a trial to assess the cardiovascular safety of obesity drug Contrave is in swing, with Orexigen Therapeutics and Takeda Pharmaceutical entering a dispute process, according to Reuters, with earlier data breaches the subject of a separate issue.

Dr. Reddy's says pick a partner to dance with Japan on pharma trade

Whatever the India government may be doing to foster pharma trade with Japan, Dr Reddy's Laboratories feels it has a better way: partner with Japan counterparts.

Celgene partners with Alliqua for a third cell-based, wound care product

Micro-cap Alliqua Biomedical has amended its exclusive licensing deal with Celgene Cellular Therapeutics, a subsidiary of Celgene, to add the right to develop and market the biopharma's connective tissue matrix product. This is the third tissue product that Alliqua has licensed from Celgene, also including the Biovance Human Amniotic Membrane Allograft and the Placental Extra Cellular Matrix.